No Data
Learning Times: Why are innovative drugs important?
① Currently, the research and development of innovative drugs is surpassing the purely Technology domain, evolving into a strategic high ground for great power competition; ② Accelerating the research and development of innovative drugs has multiple strategic significances, including addressing major disease challenges, maintaining national pharmaceutical security, promoting high-quality economic development, and participating in global health governance.
Weekend Reading | Hong Kong pharmaceutical stocks bull market: How to calculate BD value and which companies are undervalued?
Pharmaceutical stocks are rapidly becoming the champion sector for growth this year, having been quiet for two years, with frequent good news from overseas.
Hong Kong market quick view | The three major Indexes closed higher, with the Technology Index slightly up by 0.88%. Network Technology stocks rose, with Xiaomi Group increasing by nearly 2%; Gold stocks were mixed, with Zijin Gold dropping by nearly 10%.
Network Technology stocks are rising, XIAOMI-W is up 1.89%, Alibaba is up 1.55%; shipping and port stocks are higher, TSMC Shipping is up 35.68%, COSCO SHIP PORT is up 3.43%; bank stocks have increased, China Construction Bank Corporation is up 3.34%, Industrial And Commercial Bank Of China is up 2.82%.
Hong Kong stocks have fluctuated | Pharmaceutical stocks have fallen again as Trump raises the issue of drug tariffs. Institutions indicate that the trade in innovative drugs is in an overheated state.
Pharmaceutical stocks have once again declined. As of the time of writing, ASCLETIS-B (01672) is down 8.36%, trading at 8.88 HKD; VIVA BIOTECH (01873) has dropped 7.88%, at 1.52 HKD; JUNSHI BIO (01877) is down 6.03%, priced at 21.8 HKD.
Value "reassessment" is in progress! A surge of double stocks in the Hong Kong stock market's innovative drug Concept is emerging. Where are the opportunities for the Sector in the future?
After more than three years of downturn, innovative drugs in the Hong Kong stock market have welcomed an opportunity for value reassessment.
Ascletis Doses First Participants in US Phase 1 Trial of Psoriasis Drug; Shares Up 4%
